Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 May 2025 | Story André Damons | Photo Supplied
Prof Martin Nyaga
Prof Martin Nyaga, Full Professor in the Division of Virology and Head of the Next Generation Sequencing Unit (UFS-NGS Unit) at the University of the Free State.

Prof Martin Nyaga, an NRF B-Rated Full Professor in the Division of Virology and Head of the Next Generation Sequencing (UFS-NGS) Unit at the University of the Free State (UFS), has been selected as one of the cohort II fellows of the prestigious Calestous Juma Science Leadership Fellowship

Prof Nyaga, who is one of 12 individuals from six African countries (Ethiopia, Ghana, Kenya, Malawi, South Africa, and Zambia) selected to this cohort, says he is profoundly honoured. Through the prestigious fellowship, inspired by Professor Juma’s visionary legacy, he envisions advancing Africa’s capacity to combat infectious diseases by developing robust, mNGS-based surveillance systems that detect and characterise emerging pathogens early enough.

“The opportunity to join a cohort of exceptional African scientists, united by a shared commitment to addressing global health challenges, is both humbling and inspiring. I feel a deep sense of responsibility to uphold the fellowship’s mission of fostering sustainable development through cutting-edge research and policy engagement, particularly in the context of my work on genomic disease surveillance. 

“I am deeply inspired by Professor Calestous Juma’s legacy of harnessing science for sustainable development, and I am committed to embodying his optimism and interdisciplinary approach. The fellowship represents a transformative platform to advance scientific innovation and leadership in Africa. I would like to extend my gratitude to the Gates Foundation for this opportunity, and I look forward to contributing to a transformative era of African scientific leadership,” says Prof Nyaga.

 

Advantages of the Fellowship

The Calestous Juma Science Leadership Fellowship focuses on bringing together accomplished innovators to form a community of global health opinion shapers and influencers. The programme provides targeted professional development to support fellows as they expand their networks, amplify their voices, and continue to build and strengthen a dynamic, resilient research & development (R&D) ecosystem that changes the lives of people living not only in Africa but around the world.

Among the new cohort are experts in virology (including HIV and rota), bacteriology (including TB and strep), immunology, malaria, modelling, maternal immunisation, epidemiology, chemistry, drug discovery and development, vaccine discovery, clinical trials, and controlled human infection models to name just a few examples. 

According to Prof Nyaga, Director of a WHO Collaborating Centre for Vaccine Preventable Diseases (VPD) Surveillance and Pathogen Genomics, selection for the Fellowship is a rigorous and competitive process, designed to identify African scientists with exceptional research portfolios and leadership potential. Candidates are typically invited based on their established track record in transformative science, as well as their ability to anchor health and R&D initiatives within their communities. Successful applicants are evaluated for their scientific excellence, interdisciplinary networks, and commitment to mentoring the next generation of African scientists, aligning with the fellowship’s holistic view of leadership.

The NRF B3-rated scientist says he is eager to engage with the fellowship’s vibrant community of scientists from multiple African countries, fostering collaborations that amplify our collective impact on global health. He anticipates benefiting from the fellowship’s non-scientific training in communication, policy engagement, and institution strengthening. Participating in networking opportunities will broaden his perspectives and strengthen his capacity to drive innovative solutions in Africa’s genomic R&D ecosystem.

“I believe my work in pathogen surveillance research using genomics, aligns closely with the fellowship's objectives. As a fellow, I bring a wealth of experience in leading multi-country projects, establishing regional collaborations, and fostering capacity development through training and mentorship. 

“In addition, my ongoing work at the UFS-NGS Unit, including projects on enteric and respiratory virus surveillance, vaccine monitoring and efficacy using next generation sequencing, which will enrich discussions on public health. Conversely, the fellowship will enhance my scientific development by providing advanced training in leadership and policy advocacy, enabling me to translate research findings into actionable health policies. This synergy will elevate my capacity to lead transformative R&D initiatives and mentor future African scientists.” 

 

Contributing to the betterment of people 

Prof Nyaga believes his research on vaccine efficacy and metagenomics of gut and respiratory virome will contribute to the betterment of not only Africans, but also people around the world by informing targeted interventions in vaccine efficacy monitoring and development. This research will also contribute to the reduction of morbidity and mortality applicable to enteric and respiratory infections in vulnerable populations. 

Furthermore, he explains, the fellowship’s emphasis on networking and policy engagement will amplify these efforts, enabling him to advocate for evidence-based health policies across Africa. Globally, their collective work as Calestous Juma Science Leadership fellows will strengthen the R&D ecosystem, fostering innovation that addresses pandemic preparedness and other health challenges. By building resilient scientific communities, the fellowship will contribute to sustainable development, improving lives in Africa and beyond.

News Archive

Death may come in adorable little packages
2015-03-23

The main host of the Lassa virus is the Natal Mulimammate mouse.

Photo: Supplied

Postdoctoral researcher, Abdon Atangana, of the Institute for Groundwater Studies at the university recently published an article online about the Lassa Haemorrhagic fever in the Natural Computing Applications Forum. In addition to the terminal transmissible sickness recognised as Ebola haemorrhagic fever, there is another strain called Lassa haemorrhagic fever.

The disease is classified under the arenaviridae virus family. The first outbreaks of the disease were observed in Nigeria, Liberia, Sierra Leone, and the Central African Republic. However, it was first described in 1969 in the town of Lassa, in Borno State, Nigeria.

The main host of the Lassa virus is the Natal Mulimammate mouse, an animal indigenous to most of Sub-Saharan Africa. The contamination in humans characteristically takes place through exposure to animal excrement through the respiratory or gastrointestinal tracts.

Mouthfuls of air containing tiny particle of infective material are understood to be the most noteworthy way of exposure. It is also possible to acquire the infection through broken skin or mucous membranes that are directly exposed to the infective material.

“The aim of my research was to propose a novel mathematical equation used to describe the spread of the illness amongst pregnant women in West Africa. To achieve this, I used my newly-proposed derivative with fractional order called beta-derivative. Since none of the commonly used integral transform could be used to derive the solution of the proposed model, I proposed a new integral transform called Atangana-Transform, and used it, together with some iterative technique, to derive the solution of the model.

“My numerical simulations show that the disease is as deadly amongst pregnant women as Ebola,” Abdon said.

Abdon’s research was submitted to one of Springer’s top-tier journals with an impact factor 1.78. The paper was accepted and published February 2015.

Read more about Abdon’s research.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept